Company intelligence

ONC

BeiGene, Ltd. · NASDAQ · Healthcare

Price$341.80-2.62% · −$9.20

Market cap36.52BEquity value

P / E60.2Trailing ratio

Volume943.46KLatest session

Market data

ONC price chart

TradingView

Related signals

1 min delayed

Browse public ONC signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ONCMay 14, 2026-4.04% since signal

FDA Approval of BEQALZI Signals New Market Opportunity Amid Stock Decline

The FDA's approval of BEQALZI offers a new treatment for mantle cell lymphoma, showcasing promising response rates. This approval may energize investor confidence in ONC, particularly with the potential market impact set for 2026.

View signal analysis

ONCAug 29, 2025-2.16% since signal

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

BeOne released positive Phase 1/2 results for sonrotoclax in MCL patients. Study met primary overall response rate endpoint; results promising across secondary measures. FDA approval submission planned for sonrotoclax; applications under review in China. Sonrotoclax has Orphan Drug Designation for MCL, indicating potential market exclusivity. ONC stock increased by 4.46% following the positive news.

View signal analysis

Research